BACKGROUND:DAS181, a novel host-directed antiviral in development for influenza treatment, was assessed in this phase II clinical trial. METHODS: This study was a double-blind, placebo-controlled phase II clinical trial assessing influenza viral load and patient safety in otherwise healthy influenza-infected participants. Participants were randomized to a single-dose, multiple-dose, or placebo group and were followed for safety and virologic outcomes. RESULTS:A total of 177 laboratory-confirmed influenza-infected participants were enrolled in the trial, which encompassed 3 influenza seasons from 2009-2011 in both the Northern and Southern Hemispheres. Thirty-seven percent of participants had confirmed infection with influenza B, 33% with seasonal H3N2, 29% with pandemic 2009 H1N1, and 1 participant was positive for both influenza B and pandemic 2009 H1N1. Significant effects were observed in regard to decreased change from baseline viral load and viral shedding in the multiple-dose group compared with placebo as measured by quantitative polymerase chain reaction (P < .05). No instances of H274Y were observed among viral isolates from this trial. Overall, the drug was generally well tolerated. CONCLUSIONS:DAS181 significantly reduced viral load in participants infected with influenza, thus warranting future clinical development of this novel host-directed therapy. CLINICAL TRIALS.GOV IDENTIFIER: NCT01037205.
RCT Entities:
BACKGROUND: DAS181, a novel host-directed antiviral in development for influenza treatment, was assessed in this phase II clinical trial. METHODS: This study was a double-blind, placebo-controlled phase II clinical trial assessing influenza viral load and patient safety in otherwise healthy influenza-infected participants. Participants were randomized to a single-dose, multiple-dose, or placebo group and were followed for safety and virologic outcomes. RESULTS: A total of 177 laboratory-confirmed influenza-infected participants were enrolled in the trial, which encompassed 3 influenza seasons from 2009-2011 in both the Northern and Southern Hemispheres. Thirty-seven percent of participants had confirmed infection with influenza B, 33% with seasonal H3N2, 29% with pandemic 2009 H1N1, and 1 participant was positive for both influenza B and pandemic 2009 H1N1. Significant effects were observed in regard to decreased change from baseline viral load and viral shedding in the multiple-dose group compared with placebo as measured by quantitative polymerase chain reaction (P < .05). No instances of H274Y were observed among viral isolates from this trial. Overall, the drug was generally well tolerated. CONCLUSIONS: DAS181 significantly reduced viral load in participants infected with influenza, thus warranting future clinical development of this novel host-directed therapy. CLINICAL TRIALS.GOV IDENTIFIER: NCT01037205.
Authors: F G Hayden; A D Osterhaus; J J Treanor; D M Fleming; F Y Aoki; K G Nicholson; A M Bohnen; H M Hirst; O Keene; K Wightman Journal: N Engl J Med Date: 1997-09-25 Impact factor: 91.245
Authors: Michael P Malakhov; Laura M Aschenbrenner; Donald F Smee; Miles K Wandersee; Robert W Sidwell; Larisa V Gubareva; Vasiliy P Mishin; Frederick G Hayden; Do Hyong Kim; Alice Ing; Erin R Campbell; Mang Yu; Fang Fang Journal: Antimicrob Agents Chemother Date: 2006-04 Impact factor: 5.191
Authors: J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills Journal: JAMA Date: 2000-02-23 Impact factor: 56.272
Authors: Jessica A Belser; Xiuhua Lu; Kristy J Szretter; Xiaoping Jin; Laura M Aschenbrenner; Alice Lee; Stephen Hawley; Do Hyong Kim; Michael P Malakhov; Mang Yu; Fang Fang; Jacqueline M Katz Journal: J Infect Dis Date: 2007-10-31 Impact factor: 5.226
Authors: Dan Yan; Stefanie A Krumm; Aiming Sun; David A Steinhauer; Ming Luo; Martin L Moore; Richard K Plemper Journal: J Virol Date: 2013-08-07 Impact factor: 5.103
Authors: Jonathan M Zenilman; Edward J Fuchs; Craig W Hendrix; Christine Radebaugh; Robert Jurao; Seema U Nayak; Robert G Hamilton; J McLeod Griffiss Journal: Antiviral Res Date: 2015-09-25 Impact factor: 5.970
Authors: S Chalkias; M R Mackenzie; C Gay; C Dooley; F M Marty; R B Moss; T Li; R L Routh; S R Walsh; C S Tan Journal: Transpl Infect Dis Date: 2014-01-03 Impact factor: 2.228